Answers are grounded in this paper and cite their sources.
Retrospective analysis shows treatment switching and healthcare costs in Medicare patients with chronic migraine, indicating comparable expenses across treatments.
Patients with CM on a CGRP mAb were significantly more likely to switch to a different branded migraine preventive treatment within 12 months of treatment initiation compared to those on onabotA. Total costs were comparable between treatments.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: